Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Overview
Explore Neumora Therapeutics, Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.
Neumora Therapeutics, Inc. Common Stock (NMRA)
Key Financials
Key Financials
Market Cap
307.6M
P/E Ratio
-1.25
EPS (TTM)
$-1.33
ROE
-1.82%
NMRA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Neumora Therapeutics, Inc. Common Stock's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of NMRA on the NASDAQ shows an RSI of 53.07, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $2.78 for the NASDAQ listing.
Key metrics behind Neumora Therapeutics, Inc. Common Stock's NASDAQ-traded stock include a P/E ratio of -1.25 and a market capitalization of 307.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of NMRA on the NASDAQ.